BD Biosciences has unveiled enhanced multimodal assays combining protein and transcriptomic analyses to expand the resolution of single-cell studies, addressing limitations of previously RNA-only approaches. Such platforms facilitate detection of rare cell populations and nuanced immune phenotypes, particularly in complex diseases. Complementary advancements include NGS-based proteomics technologies that enable high-throughput, multiplexed protein quantification with exceptional specificity, promising to accelerate biomarker discovery and therapeutic development.